THE FIRST AND ONLY FDA APPROVED WAY TO ACCESS THE SUPRACHOROIDAL SPACE (SCS®)

Our SCS Microinjection Procedure

Clearside’s proprietary SCS injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform is inherently flexible and intended to work with established medications, new formulations of medicines, as well as future innovations, that can be delivered via suprachoroidal administration.

Clearside has received the International Organization for Standardization (ISO) Certification EN ISO 13485:2016.  The certificate can be accessed here.

CLINICALLY PROVEN FOR TARGETED DELIVERY

Clearside has developed the only clinically tested product to obtain FDA approval for suprachoroidal drug delivery. Our proprietary SCS Microinjector® can be used to inject a wide variety of therapies designed to be delivered via suprachoroidal injection in order to flow to the back of the eye. The SCS Microinjector provides targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. Suprachoroidal injection enables the rapid dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye.

  • Thousands of suprachoroidal injections performed

  • Injections performed across multiple retinal disorders

  • Safety profile comparable to intravitreal injections

  • XIPERE®: first approved therapeutic delivered into the suprachoroidal space

Our internally developed and our collaborators’ drug candidates utilize our SCS Microinjector for suprachoroidal administration to access the back of the eye.

References:
The SCS Microinjector has not been independently approved by the FDA; XIPERE® (triamcinolone acetonide injectable suspension) has been approved for suprachoroidal use with the SCS Microinjector.

Kurup, et. al, Macula Society 2021 Safety of the Suprachoroidal Injection Procedure Utilizing SCS Microinjector® across Three Retinal Disorders

Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. | Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal space: from potential space to a space with potential. Clin Ophthalmol. 2016;10:173-178. | Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:58-66.